The Hirshberg Foundation is excited to welcome a new Symposium sponsor, GRAIL, LLC, a company at the leading edge of early detection. Welcoming leading medical professionals in the field of pancreatic cancer to our Annual Symposium on Pancreatic Cancer allows our patients, caregivers and families to learn about critical and groundbreaking advances. GRAIL has joined the medical community’s efforts to empower patients to detect cancer early with their Galleri® test. We are excited to share innovative advances that offer an opportunity to detect cancer earlier and save lives.
Galleri is a multi-cancer early detection (MCED) test; it detects signals found in DNA that cancer cells shed into the bloodstream. GRAIL’s innovative testing with Galleri has detected 50 types of cancer through a simple blood draw. Galleri allowed Jim, who was featured in a NBC nightly news story, to detect pancreatic cancer at Stage II. Testing and continued early detection research broadens our understanding of pancreatic cancer and brings us closer to the goal of regular cancer screenings.
The ultimate goal of early detection is to save lives as early as possible, screen people at-risk, and empower our communities with the necessary tools to achieve better outcomes. Advances in early detection not only impact the progression of disease, it can also decrease the financial burden many patients face. “Preventing cancer in the first place or detecting it early is the best way to reduce many costs associated with cancer treatment—patient out-of-pocket costs, health care payer costs, and indirect costs.” shares the American Cancer Society, Cancer Action Network.
As a Symposium sponsor, GRAIL representatives will be available to answer questions at the Symposium and discuss this technology one-on-one with patients and families in attendance.
What you should know:
- It can detect many cancers that are not commonly screened for today, to allow for earlier treatment.
- Today, 71% of cancer deaths are caused by cancers not commonly screened for.
Information about Galleri:
- Early cancer detection Testing with ease.
- Can be easily incorporated into a routine healthcare visit.
- Actionable results if a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help your healthcare provider guide your next steps.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only. For more information about Galleri, visit www.galleri.com.